USPTO Issues Tenon Medical Three U.S. Patents

Oct 18, 2024 (wallstreet-pr.com)- Tenon Medical (NASDAQ: TNON) reported that the United States Patent and Trademark Office (USPTO) issued the Company three U.S. patents.

The first two patents, numbers 12,115,075 and 12,115,076, entitled "Sacroiliac Joint Stabilization Prostheses", are directed to Tenon's Catamaran prostheses that include unique drug delivery compositions that enhance sealing of the prostheses in SI joint bone structures and bone growth about and within the prostheses when the prostheses are implanted in a SI joint.

The third patent, 12,115,077, is entitled "Systems, Apparatus and Methods for Stabilizing Sacroiliac Joints" and covers SI joint prostheses with unique structures and configurations to correct failed SI joint stabilization with alternative commercial SI joint implants without requiring removal of the failed implant.

Richard Ginn, Tenon Medical's Co-Founder and Chief Technology Officer, commented, "We are pleased with the USPTO's recognition of the novel Catamaran(R) SI joint prostheses that will provide a best-in-class solution to specifically address the need for revision of other ineffective SI joint devices.

"The issuance of these patents reinforces Tenon's focus on innovation while simultaneously protecting our technology platform which strengthens our competitive position in the industry."

About Wall Street PR

Wall Street PR, a leading press release provider, has proudly served the financial community for over 20 years, providing timely and insightful market news. Our expert team delivers customized press releases that enhance visibility for businesses and investors. With an extensive distribution network and a commitment to accuracy and strategic communications, Wall Street PR ensures that your message reaches the right audience with maximum impact. When Wall Street PR writes about a company, investors pay attention.
[email protected]

Cautionary Statement Regarding Forward Looking Information

Statements in this press release about the Company's future and expectations other than historical facts are "forward-looking statements." These statements are made based on management's current views and assumptions. As a result, there can be no assurance that management's expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as "believes," "plans," "expects," "anticipates," "foresees," "estimated," "hopes," "if," "develops," "researching," "research," "pilot," "potential," "could" or other words or phrases of similar import. Forward-looking statements include descriptions of the Company's business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.

The post USPTO Issues Tenon Medical Three U.S. Patents appeared first on WSTPR.

COMTEX_458930046/2771/2024-10-18T10:07:53

You May Also Be Interested In

• Upstream Bio Presents New Responder Analyses Demonstrating Clinically Meaningful Improvements in CRSwNP in Significant Majority of Participants Treated with Verekitug in the Phase 2 VIBRANT Trial at E
• SAMARITAN'S PURSE EBOLA TREATMENT CENTERS OPEN IN THE EPICENTER OF THE DEADLY OUTBREAK
• Mineralys Therapeutics Presents Late-Breaking Data on Lorundrostat and Heart Failure Risk Biomarkers at The Endocrine Society Annual Meeting (ENDO 2026)